Wang P, Zhou H, Han G, Ni Q, Dai S, Huang J, et al. Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression. World J Surg Oncol. 2021;19:205. https://doi.org/10.1186/s12957-021-02304-4.

Article  PubMed  PubMed Central  Google Scholar 

Kammerer-Jacquet SF, Deleuze A, Saout J, Mathieu R, Laguerre B, Verhoest G, et al. Targeting the PD-1/PD-L1 pathway in renal cell carcinoma. Int J Mol Sci. 2019;20. https://doi.org/10.3390/ijms20071692.

Luo L, Lv M, Zhuang X, Zhang Q, Qiao T. Irradiation increases the immunogenicity of Lung cancer cells and irradiation-based Tumor cell vaccine elicits tumor-specific T cell responses in vivo. OncoTargets and Therapy. 2019;12:3805–15. https://doi.org/10.2147/ott.S197516.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng Y, Dong Y, Hou Q, Wu J, Zhang W, Tian H, et al. The protective effects of XH-105 against radiation-induced intestinal injury. J Cell Mol Med. 2019;23:2238–47. https://doi.org/10.1111/jcmm.14159.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for patients with metastatic castration-resistant Prostate Cancer. Clin Cancer Res. 2023;29:1651–7. https://doi.org/10.1158/1078-0432.Ccr-22-2875.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Donoghue JA, Bardiès M, Wheldon TE. Relationships between Tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nuclear Medicine: Official Publication Soc Nuclear Med. 1995;36:1902–9.

Google Scholar 

Hindié E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose deposits from 90Y, 177Lu, 111In, and 161 Tb in Micrometastases of various sizes: implications for Radiopharmaceutical Therapy. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2016;57:759–64. https://doi.org/10.2967/jnumed.115.170423.

Article  CAS  Google Scholar 

Türeci O, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011;481:83–92. https://doi.org/10.1016/j.gene.2011.04.007.

Article  CAS  PubMed  Google Scholar 

Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624–34. https://doi.org/10.1158/1078-0432.Ccr-08-1547.

Article  CAS  PubMed  Google Scholar 

Baek JH, Park DJ, Kim GY, Cheon J, Kang BW, Cha HJ, et al. Clinical implications of Claudin18.2 expression in patients with gastric Cancer. Anticancer Res. 2019;39:6973–9. https://doi.org/10.21873/anticanres.13919.

Article  CAS  PubMed  Google Scholar 

Kyuno D, Takasawa A, Takasawa K, Ono Y, Aoyama T, Magara K, et al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022;10:1967080. https://doi.org/10.1080/21688370.2021.1967080.

Article  CAS  PubMed  Google Scholar 

Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet (London England). 2023;401:1655–68. https://doi.org/10.1016/s0140-6736(23)00620-7.

Article  CAS  PubMed  Google Scholar 

Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32:609–19. https://doi.org/10.1016/j.annonc.2021.02.005.

Article  CAS  PubMed  Google Scholar 

Lordick F, Al-Batran SE, Ganguli A, Morlock R, Sahin U, Türeci Ö. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2 + gastroesophageal adenocarcinoma. Gastric cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2021;24:721–30. https://doi.org/10.1007/s10120-020-01153-6.

Article  CAS  PubMed  Google Scholar 

Hristodorov D, Fischer R, Linden L. With or without sugar? (A)glycosylation of therapeutic antibodies. Mol Biotechnol. 2013;54:1056–68. https://doi.org/10.1007/s12033-012-9612-x.

Article  CAS  PubMed  Google Scholar 

Wei W, Liu Q, Jiang D, Zhao H, Kutyreff CJ, Engle JW et al. Tissue factor-targeted ImmunoPET imaging and Radioimmunotherapy of anaplastic thyroid Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2020;7:1903595. https://doi.org/10.1002/advs.201903595.

Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347–60. https://doi.org/10.1038/nrc3925.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Green DJ, O’Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, et al. CD38-bispecific antibody pretargeted radioimmunotherapy for Multiple Myeloma and other B-cell malignancies. Blood. 2018;131:611–20. https://doi.org/10.1182/blood-2017-09-807610.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheal SM, Xu H, Guo HF, Patel M, Punzalan B, Fung EK, et al. Theranostic pretargeted radioimmunotherapy of internalizing solid Tumor antigens in human Tumor xenografts in mice: curative treatment of HER2-positive breast carcinoma. Theranostics. 2018;8:5106–25. https://doi.org/10.7150/thno.26585.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, et al. Alpha radioimmunotherapy using (225)Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics. 2020;10:11359–75. https://doi.org/10.7150/thno.48810.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hennrich U, Eder M. [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): the first FDA-Approved Radiotherapeutical for treatment of Prostate Cancer. Pharmaceuticals (Basel Switzerland). 2022;15. https://doi.org/10.3390/ph15101292.

Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Prostate-specific membrane Antigen Radioligand Therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant Prostate Cancer: comparison of Safety, Biodistribution, and Dosimetry. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2022;63:1199–207. https://doi.org/10.2967/jnumed.121.262713.

Article  CAS  Google Scholar 

Chen Y, Hou X, Li D, Ding J, Liu J, Wang Z, et al. Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors. J Pharm Anal. 2023;13:367–75. https://doi.org/10.1016/j.jpha.2023.02.011.

Article  PubMed  PubMed Central  Google Scholar 

Teng F, Gu Y, Chai H, Guo H, Li H, Wu X, et al. Abstract 5183: the preclinical characterization of TST001, a novel humanized anti-claudin18.2 mAb with enhanced binding affinity and anti-tumor activity. Cancer Res. 2020;80:5183–. https://doi.org/10.1158/1538-7445.AM2020-5183.

Article  Google Scholar 

Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC, et al. claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. 2001;21:7380–90. https://doi.org/10.1128/mcb.21.21.7380-7390.2001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang S, Qi C, Ding J, Li D, Zhang M, Ji C, et al. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system Neoplasms enables whole-body target mapping and lesion detection. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06234-z.

Article  PubMed  PubMed Central  Google Scholar 

Wei W, Zhang D, Zhang Y, Li L, Jin Y, An S et al. Development and comparison of (68)Ga/(18)F/(64)Cu-labeled nanobody tracers probing Claudin18.2. Molecular therapy oncolytics. 2022;27:305–14. https://doi.org/10.1016/j.omto.2022.11.003.